SG11202007578SA - Antibodies binding to gprc5d - Google Patents

Antibodies binding to gprc5d

Info

Publication number
SG11202007578SA
SG11202007578SA SG11202007578SA SG11202007578SA SG11202007578SA SG 11202007578S A SG11202007578S A SG 11202007578SA SG 11202007578S A SG11202007578S A SG 11202007578SA SG 11202007578S A SG11202007578S A SG 11202007578SA SG 11202007578S A SG11202007578S A SG 11202007578SA
Authority
SG
Singapore
Prior art keywords
gprc5d
antibodies binding
antibodies
binding
Prior art date
Application number
SG11202007578SA
Inventor
Georg Fertig
Christian Klein
Stefan Lorenz
Wei Xu
Marie-Luise Bernasconi
Alexander Bujotzek
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11202007578SA publication Critical patent/SG11202007578SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/522CH1 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202007578SA 2018-02-09 2019-02-07 Antibodies binding to gprc5d SG11202007578SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18156014 2018-02-09
PCT/EP2019/052962 WO2019154890A1 (en) 2018-02-09 2019-02-07 Antibodies binding to gprc5d

Publications (1)

Publication Number Publication Date
SG11202007578SA true SG11202007578SA (en) 2020-09-29

Family

ID=61189309

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007578SA SG11202007578SA (en) 2018-02-09 2019-02-07 Antibodies binding to gprc5d

Country Status (20)

Country Link
US (3) US20210054094A1 (en)
EP (1) EP3749692A1 (en)
JP (1) JP2023159115A (en)
KR (1) KR20200119833A (en)
CN (1) CN111788231A (en)
AR (1) AR117392A1 (en)
AU (1) AU2019219061A1 (en)
BR (1) BR112020015297A2 (en)
CA (1) CA3088730A1 (en)
CL (2) CL2020001854A1 (en)
CO (1) CO2020008940A2 (en)
CR (1) CR20200341A (en)
IL (1) IL276537A (en)
MA (1) MA51734A (en)
MX (1) MX2020007012A (en)
PE (1) PE20201341A1 (en)
PH (1) PH12020551211A1 (en)
SG (1) SG11202007578SA (en)
TW (1) TWI829667B (en)
WO (1) WO2019154890A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR106188A1 (en) 2015-10-01 2017-12-20 Hoffmann La Roche ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE
WO2020127618A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted agonistic cd28 antigen binding molecules
BR112022001460A2 (en) * 2019-07-31 2022-03-22 Hoffmann La Roche Bispecific antigen-binding molecules, one or more isolated polynucleotides, host cell, method for producing a bispecific antigen-binding molecule and for treating a disease in an individual, pharmaceutical composition, use of the bispecific antigen-binding molecule and invention
BR112022025250A2 (en) * 2020-06-19 2022-12-27 Hoffmann La Roche MOLECULES, ONE OR MORE POLYNUCLEOTIDES, ONE OR MORE VECTORS, HOST CELL, METHODS FOR PRODUCING A MOLECULE AND INDUCING LYSIS OF A CELL, PHARMACEUTICAL COMPOSITION, USE OF THE MOLECULE, METHODS OF TREATMENT OF A DISEASE AND INVENTION
WO2022148370A1 (en) * 2021-01-05 2022-07-14 Lanova Medicines Development Co., Ltd. Anti-gprc5d monoclonal antibodies and uses thereof
IL304052A (en) * 2021-01-05 2023-08-01 Lanova Medicines Dev Co Ltd Anti-gprc5d monoclonal antibodies and uses thereof
BR112023016121A2 (en) 2021-02-16 2023-11-28 Janssen Pharmaceutica Nv TRIESPECIFIC ANTIBODY TARGETING BCMA, GPRC5D AND CD3
AU2022223152A1 (en) 2021-02-19 2023-08-31 Innovent Biologics (Suzhou) Co., Ltd. Anti-gprc5d×bcma×cd3 trispecific antibody and use thereof
CN116063500A (en) * 2021-08-30 2023-05-05 原启生物科技(上海)有限责任公司 anti-GPRC 5D antigen binding proteins and uses thereof
CN118159565A (en) * 2021-11-05 2024-06-07 正大天晴药业集团股份有限公司 Antibodies that bind GPRC5D and uses thereof
WO2023173272A1 (en) * 2022-03-15 2023-09-21 上海驯鹿生物技术有限公司 Gprc5d-targeting fully humanized chimeric antigen receptor (car) and use thereof
WO2023115347A1 (en) * 2021-12-21 2023-06-29 上海驯鹿生物技术有限公司 Fully human antibody targeting gprc5d
WO2023125728A1 (en) * 2021-12-31 2023-07-06 康源博创生物科技(北京)有限公司 Anti-gprc5d antibody and use thereof
WO2023125729A1 (en) * 2021-12-31 2023-07-06 康源博创生物科技(北京)有限公司 Anti-cd3 humanized antibody and application thereof in preparation of bispecific antibody
WO2023125888A1 (en) * 2021-12-31 2023-07-06 山东先声生物制药有限公司 Gprc5d antibody and application thereof
WO2023143537A1 (en) * 2022-01-29 2023-08-03 恺兴生命科技(上海)有限公司 Gprc5d antibody and use thereof
WO2023227062A1 (en) * 2022-05-27 2023-11-30 Antengene (Hangzhou) Biologics Co., Ltd. Novel anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
WO2024002308A1 (en) * 2022-06-30 2024-01-04 康诺亚生物医药科技(成都)有限公司 Development and use of novel multispecific tumor inhibitor
WO2024031091A2 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
CN116003598B (en) * 2022-08-30 2024-04-26 苏州缔码生物科技有限公司 Recombinant humanized monoclonal antibody targeting human GPRC5D and application thereof
WO2024050797A1 (en) * 2022-09-09 2024-03-14 北京天广实生物技术股份有限公司 Multispecific antibody binding to bcma, gprc5d and cd3, and use thereof
WO2024079010A1 (en) 2022-10-10 2024-04-18 F. Hoffmann-La Roche Ag Combination therapy of a gprc5d tcb and cd38 antibodies
WO2024079015A1 (en) 2022-10-10 2024-04-18 F. Hoffmann-La Roche Ag Combination therapy of a gprc5d tcb and imids
WO2024079009A1 (en) 2022-10-10 2024-04-18 F. Hoffmann-La Roche Ag Combination therapy of a gprc5d tcb and proteasome inhibitors
CN117924485A (en) * 2022-10-25 2024-04-26 上海祥耀生物科技有限责任公司 Multi-specific antibody for resisting GPRC5D
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7802170A (en) 1977-04-18 1978-10-20 Hitachi Metals Ltd JEWELRY.
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
ES2052027T5 (en) 1988-11-11 2005-04-16 Medical Research Council IMMUNOGLOBULINE VARIABLE DOMAIN SEQUENCE CLONING.
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ES2246069T3 (en) 1997-05-02 2006-02-01 Genentech, Inc. PROCEDURE FOR THE PREPARATION OF MULTI-SPECIFIC ANTIBODIES THAT HAVE COMMON AND MULTIMERIC COMPONENTS.
ATE296315T1 (en) 1997-06-24 2005-06-15 Genentech Inc COMPOSITIONS CONTAINING GALACTOSYLATED GLYCOPROTEINS AND METHOD FOR THE PRODUCTION THEREOF
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ATE419009T1 (en) 1997-10-31 2009-01-15 Genentech Inc METHODS AND COMPOSITIONS CONSISTING OF GLYCOPROTEIN GLYCOFORMS
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (en) 1997-12-05 2012-01-30 Scripps Research Inst Humanization of murine antibody
PT1071700E (en) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100797667B1 (en) 1999-10-04 2008-01-23 메디카고 인코포레이티드 Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US20030180714A1 (en) 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2405944T3 (en) 2000-11-30 2013-06-04 Medarex, Inc. Nucleic acids encoding reorganized human immunoglobulin sequences from transgenic transchromosomal mice zadas
CA2838062C (en) 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
CN102911987B (en) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 The adorned cell of genome
WO2003085118A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
BRPI0316779B1 (en) 2002-12-16 2020-04-28 Genentech Inc humanized antibody that binds human cd20, composition, manufactured article, apoptosis induction method, cd20 positive cancer treatment method, autoimmune disease treatment methods, isolated nucleic acids, expression vectors, host cells, method for producing a humanized 2h7 antibody, isolated polypeptide, liquid formulation, method of treating rheumatoid arthritis (ra) and humanized cd20 binding antibodies
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
AU2004205802B2 (en) 2003-01-22 2009-11-05 Roche Glycart Ag Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PL1737891T3 (en) 2004-04-13 2013-08-30 Hoffmann La Roche Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
RU2488597C2 (en) 2005-02-07 2013-07-27 Гликарт Биотехнологи Аг Antigen-binding molecules, which bind egfr, their coding vectors and their usage
TWI671403B (en) 2005-03-31 2019-09-11 中外製藥股份有限公司 Method for controlling controlled assembly of polypeptide
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
PT1999154E (en) 2006-03-24 2013-01-24 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US20080044455A1 (en) 2006-08-21 2008-02-21 Chaim Welczer Tonsillitus Treatment
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
CN101687915B8 (en) 2007-04-03 2018-08-03 安进研发(慕尼黑)股份有限公司 Cross-species-specific cd 3-epsilon binding domain
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
SI2235064T1 (en) 2008-01-07 2016-04-29 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
BRPI1014089A2 (en) 2009-04-02 2016-04-19 Roche Glycart Ag multispecific antibodies comprising full length antibodies and single chain fab fragments
JP5616428B2 (en) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト Trivalent bispecific antibody
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
SG176219A1 (en) 2009-05-27 2011-12-29 Hoffmann La Roche Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
NZ598962A (en) 2009-09-16 2014-12-24 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
PT2519543T (en) 2009-12-29 2016-10-07 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CA2799540A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
CN103429620B (en) 2010-11-05 2018-03-06 酵活有限公司 There is the antibody design of the stable heterodimeric of mutation in Fc domains
MX354359B (en) 2011-03-29 2018-02-28 Roche Glycart Ag Antibody fc variants.
EP2748202B1 (en) 2011-08-23 2018-07-04 Roche Glycart AG Bispecific antigen binding molecules
RU2605390C2 (en) 2011-08-23 2016-12-20 Рош Гликарт Аг Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
JP6339015B2 (en) 2011-08-23 2018-06-06 ロシュ グリクアート アーゲー Bispecific T cell activation antigen binding molecule
EP2794905B1 (en) 2011-12-20 2020-04-01 MedImmune, LLC Modified polypeptides for bispecific antibody scaffolds
TR201808458T4 (en) 2012-02-15 2018-07-23 Hoffmann La Roche FC-receptor based affinity chromatography.
ES2743399T3 (en) 2012-04-20 2020-02-19 Merus Nv Methods and means for the production of Ig-like heterodimeric molecules
KR101833602B1 (en) * 2013-02-26 2018-02-28 로슈 글리카트 아게 Bispecific t cell activating antigen binding molecules
WO2015095539A1 (en) 2013-12-20 2015-06-25 Genentech, Inc. Dual specific antibodies
UA117289C2 (en) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Multispecific antibodies
EP3174897B1 (en) 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Multispecific antibodies
MA40510A (en) 2014-08-04 2017-06-14 Hoffmann La Roche BISPECIFIC T-LYMPHOCYTE ACTIVATE ANTIGEN-BINDING MOLECULES
US10077318B2 (en) 2014-09-12 2018-09-18 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2016055593A1 (en) * 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
KR20170070070A (en) 2014-10-24 2017-06-21 에프. 호프만-라 로슈 아게 Vh-vl-interdomain angle based antibody humanization
MX2017007247A (en) * 2014-12-05 2018-01-25 Memorial Sloan Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use.
IL290488B1 (en) * 2015-04-13 2024-03-01 Pfizer Therapeutic antibodies and their uses
KR102668727B1 (en) 2015-04-24 2024-05-28 제넨테크, 인크. Multispecific antigen-binding protein
TWI781108B (en) * 2016-07-20 2022-10-21 比利時商健生藥品公司 Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
WO2018117786A1 (en) 2016-12-19 2018-06-28 Campo Y Ramos Juan Carlos Method for scientific self-adjusting moulding based on real-time recurrent learning

Also Published As

Publication number Publication date
AU2019219061A1 (en) 2020-08-06
CL2023000907A1 (en) 2023-11-17
MA51734A (en) 2021-05-19
CN111788231A (en) 2020-10-16
CO2020008940A2 (en) 2020-08-31
CR20200341A (en) 2020-11-02
US20230212308A1 (en) 2023-07-06
TW201936641A (en) 2019-09-16
RU2020129004A (en) 2022-03-09
CA3088730A1 (en) 2019-08-15
AR117392A1 (en) 2021-08-04
PH12020551211A1 (en) 2021-05-17
PE20201341A1 (en) 2020-11-25
JP2021513334A (en) 2021-05-27
CL2020001854A1 (en) 2020-10-23
IL276537A (en) 2020-09-30
JP2023159115A (en) 2023-10-31
KR20200119833A (en) 2020-10-20
US20240067749A1 (en) 2024-02-29
EP3749692A1 (en) 2020-12-16
US20210054094A1 (en) 2021-02-25
MX2020007012A (en) 2020-09-07
WO2019154890A1 (en) 2019-08-15
TWI829667B (en) 2024-01-21
BR112020015297A2 (en) 2020-12-08

Similar Documents

Publication Publication Date Title
IL276537A (en) Antibodies binding to gprc5d
IL283939A (en) Antibodies binding to cd3
ZA202203250B (en) Cd3 binding antibodies
IL287613A (en) Antibodies binding to gprc5d
IL263840A (en) Cd3 binding antibodies
HRP20181802T1 (en) Human cd3 binding antibody
ZA201808209B (en) Antibody for binding to interleukin 4 receptor
IL269240A (en) Antibodies binding to vista at acidic ph
IL279894A (en) Antibodies binding to ilt4
ZA201906358B (en) Improved antigen binding receptors
ZA201804317B (en) Altered april binding antibodies
ZA201905341B (en) Antibodies specifically binding to human il-1r7
IL282590A (en) Heavy chain antibodies binding to cd38
IL269394A (en) Antibodies binding to steap-1
GB201709379D0 (en) Humanised ADAMTS13 binding antibodies
GB201715149D0 (en) IL-ß binding antibody
SG11202105718TA (en) Modified antibodies